Cargando…

Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis

The glucagon-like peptide-1 receptor agonists (GLP-1RA) are among the newest treatment options available for managing of type 2 diabetes mellitus and slowing the progression of diabetes kidney disease (DKD). Subcutaneous (SC) semaglutide (Ozempic<sup>®</sup>) is a GLP-1RA with an extende...

Descripción completa

Detalles Bibliográficos
Autores principales:	De la Flor, José C., Lorenzo, Javier Deira, Marschall, Alexander, Valga, Francisco, Vázquez, Tania Monzón, Cícero, Elisa Ruiz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710441/ https://www.ncbi.nlm.nih.gov/pubmed/36465574 http://dx.doi.org/10.1159/000527919

Ejemplares similares

Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review
por: De La Flor, José C., et al.
Publicado: (2021)

Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients—A Report of 10 Cases
por: De La Flor, José C., et al.
Publicado: (2021)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
por: De La Flor, José C., et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients
por: Deira, Javier, et al.
Publicado: (2019)

Incremental short daily home hemodialysis: a case series
por: Toth-Manikowski, Stephanie M., et al.
Publicado: (2017)

Hemodialysis Initiation in Oldest-Old Patients: A Case Series
por: Maenosono, Ryoichi, et al.
Publicado: (2021)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
por: Kim, Hwi Seung, et al.
Publicado: (2021)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
por: Ren, Qingjuan, et al.
Publicado: (2022)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

SARS-CoV-2 screening in chronic hemodialysis patients in a third-level hospital and its peripheral centers: ‘one hour less in the Canary Islands’()
por: Valga, Francisco, et al.
Publicado: (2021)

Narrative Review of Incremental Hemodialysis
por: Murea, Mariana, et al.
Publicado: (2019)

Expanded hemodialysis: what’s up, Doc?
por: García-Prieto, Ana, et al.
Publicado: (2023)

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
por: Jensen, Anders Boisen, et al.
Publicado: (2023)

Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
por: Di Loreto, Chiara, et al.
Publicado: (2022)

Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series
por: Gurevich, Michael I., et al.
Publicado: (2015)

Role of extended hemodialysis in COVID-19: a case report()
por: Valga, Francisco, et al.
Publicado: (2020)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists
por: Crabtree, Thomas S. J., et al.
Publicado: (2022)

Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
por: Di Loreto, Chiara, et al.
Publicado: (2022)

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
por: Ard, Jamy, et al.
Publicado: (2021)

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
por: Chuong, Vicky, et al.
Publicado: (2023)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Incremental and Personalized Hemodialysis Start: A New Standard of Care
por: Torreggiani, Massimo, et al.
Publicado: (2022)

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China
por: Feng, Zhen, et al.
Publicado: (2023)

Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists
por: Gill, Lisa, et al.
Publicado: (2021)

Infective spondylodiscitis in patients on maintenance hemodialysis: a case series
por: Lu, Yueh-An, et al.
Publicado: (2016)

Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?
por: Touzot, Maxime, et al.
Publicado: (2022)

Incremental Hemodialysis: What We Know so Far
por: Soi, Vivek, et al.
Publicado: (2022)

Australian Workshops on Patients’ Perspectives on Hemodialysis and Incremental Start
por: Hegerty, Katharine, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9c0le5s4jlkdi0aiaoevajku0c